Little (a), Big Risk: G3 Therapeutics Sets Out to Unravel Lp(a)-Driven Cardiovascular Disease (Lipoprotein(a)-Driven Cardiovascular Disease)

G3 is trailblazing the next frontier of cardiovascular disease SAN FRANCISCO, Jan. 4, 2024 /PRNewswire/ — G3 Therapeutics (“G3”), a global leader in the use of multiomic biological Big Data, has initiated a groundbreaking initiative to unravel the contribution of Lipoprotein(a) [“Lp(a)”]…

Click here to view original post